Division of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, 1-1 Yazakokarimata, Nagakute-City, Aichi, 480-1195, Japan.
Department of Radiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute-City, Aichi, 480-1195, Japan.
BMC Med Imaging. 2024 Aug 1;24(1):200. doi: 10.1186/s12880-024-01369-3.
The objective of this study was to evaluate the intramammary distribution of MRI-detected mass and focus lesions that were difficult to identify with conventional B-mode ultrasound (US) alone. Consecutive patients with lesions detected with MRI but not second-look conventional B-mode US were enrolled between May 2015 and June 2023. Following an additional supine MRI examination, we performed third-look US using real-time virtual sonography (RVS), an MRI/US image fusion technique. We divided the distribution of MRI-detected mammary gland lesions as follows: center of the mammary gland versus other (superficial fascia, deep fascia, and atrophic mammary gland). We were able to detect 27 (84%) of 32 MRI-detected lesions using third-look US with RVS. Of these 27 lesions, 5 (19%) were in the center of the mammary gland and 22 (81%) were located in other areas. We were able to biopsy all 27 lesions; 8 (30%) were malignant and 19 (70%) were benign. Histopathologically, three malignant lesions were invasive ductal carcinoma (IDC; luminal A), one was IDC (luminal B), and four were ductal carcinoma in situ (low-grade). Malignant lesions were found in all areas. During this study period, 132 MRI-detected lesions were identified and 43 (33%) were located in the center of the mammary gland and 87 (64%) were in other areas. Also, we were able to detect 105 of 137 MRI-detected lesions by second-look conventional-B mode US and 38 (36%) were located in the center of the mammary gland and 67 (64%) were in other areas. In this study, 81% of the lesions identified using third-look US with RVS and 64% lesions detected by second-look conventional-B mode US were located outside the center of the mammary gland. We consider that adequate attention should be paid to the whole mammary gland when we perform third-look US using MRI/US fusion technique.
本研究的目的是评估 MRI 检测到的肿块和局灶性病变的乳腺内分布情况,这些病变仅通过传统的 B 型超声(US)难以识别。连续入组了 2015 年 5 月至 2023 年 6 月期间因 MRI 检查发现病变但二次常规 B 型 US 检查未见异常的患者。在进行额外的仰卧位 MRI 检查后,我们使用实时虚拟超声(RVS),一种 MRI/US 图像融合技术进行第三次超声检查。我们将 MRI 检测到的乳腺病变的分布分为以下几类:乳腺中央区与其他部位(浅筋膜、深筋膜和萎缩乳腺)。我们使用 RVS 进行第三次超声检查,共发现 27 个(84%)MRI 检测到的病变。这 27 个病变中,5 个(19%)位于乳腺中央区,22 个(81%)位于其他部位。我们对所有 27 个病变进行了活检,其中 8 个(30%)为恶性,19 个(70%)为良性。组织病理学检查显示,3 个恶性病变为浸润性导管癌(IDC;管腔 A 型),1 个为 IDC(管腔 B 型),4 个为导管原位癌(低级别)。所有病变均位于各部位。在此研究期间,共发现 132 个 MRI 检测到的病变,其中 43 个(33%)位于乳腺中央区,87 个(64%)位于其他部位。我们还通过第二次常规 B 型 US 检查发现了 137 个 MRI 检测到的病变中的 105 个,其中 38 个(36%)位于乳腺中央区,67 个(64%)位于其他部位。在本研究中,RVS 第三次超声检查发现的病变中有 81%位于乳腺中央区以外,第二次常规 B 型 US 检查发现的病变中有 64%位于乳腺中央区以外。我们认为,在使用 MRI/US 融合技术进行第三次超声检查时,应充分关注整个乳腺。